Since its initiation in 2012, Translational Lung Cancer Research (TLCR) has been developing at a speedy pace with increasing readership and citations. In order to better serve the needs of readers and authors who have submitted or who might be going to submit manuscripts for publication to the Journal, the TLCR will move from a bimonthly to a monthly publication schedule beginning in January 2021.
The frequency increase in 2021 allows TLCR to accommodate the volume of high-quality submissions it receives and will shorten each paper's time to publication, while maintaining the journal's high-quality standards.
Translational Lung Cancer Research is an international, peer-reviewed, open-access journal indexed by Science Citation Index Expanded (SCIE) and PubMed/PubMed Central, dedicated to focus on cutting-edge developments at the transition from preclinical to clinical research and thus closes the gap between "bench and bedside". The editors welcome the submission of manuscripts focusing on prevention, early detection, diagnosis, and treatment of lung cancer and related thoracic diseases, including multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer and relevant thoracic diseases.
Editorial Office
Translational Lung Cancer Research
December 3, 2020